Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 4,803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Not applicable Interventional Results available

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

NCT03199638
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, Immune System Diseases, Metabolic Diseases
Interventions
Glutamine vs. Placebo, Exercise
Drug · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

NCT00309985
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
androgen-deprivation therapy, docetaxel
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
343
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Imaging Lung Function Using Oxygen Enhanced MRI

NCT01731015
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease
Interventions
Medical Grade Oxygen
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

NCT04109313
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

NCT01703559
View directory record Official record
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00267696
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Bevacizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Early Phase 1 Interventional

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

NCT04065555
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 25, 2026, 8:17 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

NCT01989897
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol
Drug
Lead sponsor
Bryan Martin, DO
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 8:17 PM EDT
Recruiting No phase listed Observational

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

NCT00001406
View directory record Official record
Conditions
Immune System Diseases, Eosinophilia, Helminthiasis, Hypersensitivity, Parasitic Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

NCT06309355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
YR001 ointment, Placebo
Drug · Other
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

NCT04800315
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
62
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 25, 2026, 8:17 PM EDT
Completed No phase listed Observational

The Effects of a Standardized Management Plan on Children With Critical Asthma

NCT01785017
View directory record Official record
Conditions
Children, Asthma
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

NCT01049243
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide Cream 0.1%
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 25, 2026, 8:17 PM EDT
Completed No phase listed Observational

Role of T-Cells in Asthma

NCT00001408
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men

NCT01787617
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes
Interventions
Aerobic Plus Resistance Training Group, Control Group
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

NCT05014568
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tapinarof cream, 1%, Vehicle cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 25, 2026, 8:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Relationship Between Systemic Fatty Acid Availability and Insulin Sensitivity

NCT01452048
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 25, 2026, 8:17 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

NCT04200989
View directory record Official record
Conditions
Food Allergy Peanut
Interventions
Peanut allergen
Biological
Lead sponsor
Scripps Health
Other
Eligibility
15 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Not applicable Interventional Results available

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

NCT03981926
View directory record Official record
Conditions
Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
Interventions
Team-Based Connected Health (TCH)
Other
Lead sponsor
University of Southern California
Other
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676
View directory record Official record
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments

NCT03051347
View directory record Official record
Conditions
Atopic Dermatitis, Ichthyosis, Psoriasis
Interventions
Itch Questionnaire and Interview, Stigma Questionnaire and Interview, Cognitive Interview and PROMIS Itch Questionnaire
Other
Lead sponsor
Northwestern University
Other
Eligibility
0 Years to 17 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 25, 2026, 8:17 PM EDT
Recruiting Not applicable Interventional

The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

NCT07027826
View directory record Official record
Conditions
Dysphagia, Eosinophilic Esophagitis
Interventions
Esophageal string test
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Restoring Emotional, Sexual, and Physical Empowerment Through CBT & Trauma-sensitive Care: A Chronic Pelvic Pain Intervention

NCT02588885
View directory record Official record
Conditions
Pelvic Pain, Stress Disorders, Traumatic
Interventions
Trauma-sensitive Care
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 25, 2026, 8:17 PM EDT